Cancer Diagnostics

“The following table summarizes our research and development expenses for the three months ended June 30, 2026 and 2025, together with the changes in those items in dollars (in thousands): 24 Table of Contents Three Months Ended June 30, Period to Period 2026 2025 Change External research and development expenses $ 20,794 $ 20,831 $ (37 ) Employee-related expenses 11,729 16,968 (5,239 ) Facility expenses 21,708 23,265 (1,557 ) Stock-based compensation expenses 7,840 7,805 35 Sublicense and license fees 5,081 728 4,353 Other expenses — 297 (297 ) Total research and development expenses $ 67,152 $ 69,894 $ (2,742 ) The decrease of approximately $2.7 million was primarily attributable to a decrease in employee-related costs and facility-related expenses, offset by an increase in license fees.”

CRSP 10-Q · 2026-08-03

“Interest Expense Three Months Ended June 30, Change (in thousands, except percentages) 2026 2025 $ % Interest expense $ (2,694 ) $ (2,948 ) $ 254 (9)% The $0.3 million decrease in interest expense was primarily attributable to the early settlement of our revenue interest liability under the Purchase Agreement.”

ADPT 10-Q · 2026-08-04

“The blood laboratory increase was primarily driven by an increase in materials and related testing costs of $8.6 million, an increase in labor costs of $1.2 million, and a $0.9 million increase in utilities, rent, and allocated overhead, offset by a decrease in depreciation expense of $0.8 million.”

CAI 10-Q · 2026-08-05